|
To sign up for news alerts about Quintessence Biosciences, please fill out this form: http://eepurl.com/k4l49 |
| |
Press
Releases |
15 June 2012 |
| Quintessence Biosciences Meeting with Partners at 2012 BIO International Convention (PDF) |
| |
31 May 2012 |
| Quintessence Biosciences Presents on Phase I trial of Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Annual Meeting (PDF) |
| |
19 April 2012 |
| Quintessence Biosciences Selected for Buzz of BIO at 2012 BIO International Convention (PDF) |
| |
12 April 2012 |
| Quintessence Biosciences Announces Election of Walter Dewey to Board of Directors (PDF) |
| |
30 March 2012 |
| Quintessence Biosciences Presents Results for Combination Studies of Clinical Stage Ribonuclease QBI-139 at AACR Meeting (PDF) |
| |
15 January 2010 |
| Quintessence Biosciences to Present at Keystone Symposia’s RNA Silencing Conference (PDF) |
| |
13 January 2010 |
| Quintessence Biosciences Announces Expansion to The University of Texas M. D. Anderson Cancer Center of the Cancer Clinical Trial for QBI-139 (PDF) |
| |
6
January 2010 |
| Quintessence Biosciences to Present at OneMedForum 2010 (PDF) See an interview with Laura Strong, President and COO of Quintessence, at the OneMedForum 2010 (link) |
| |
8 December 2009 |
| Quintessence President and COO, Laura Strong, Talks with Joan Gillman and Jody Glynn Patrick from In Business with Joan and Jody on Madison WTDY 1670 (link) |
| |
13
November 2009 |
| Quintessence Biosciences to Present QBI-139 Data at International Cancer Conference(PDF) |
| |
3
September 2009 |
| Quintessence Gets Support from the National Cancer Institute for Next Generation EVade™ RNases (PDF) |
| |
26
March 2009 |
| Patients
Now Enrolling in Phase I Human Trial for Quintessence Biosciences
Cancer Drug, QBI-139 (PDF) |
| |
5
December 2008 |
| Quintessence
Biosciences Cancer Drug, QBI-139, Clears FDA Review to Start Phase
I Human Trial (PDF). |
| |
23
October 2008 |
|
Quintessence Biosciences Present Efficacy Data for Next Generation
EVade™ Ribonucleases at Cancer Meeting (PDF) |
| |
6
October 2008 |
| Federal
Contract Awarded to Quintessence Biosciences (PDF)
Funding will support development of Next Generation EVade™
Ribonuclease Drug Candidates. |
| |
14
April 2008 |
Quintessence
Biosciences, Inc. Presents IND-Enabling Toxicology Data at Cancer
Meeting (PDF)
At the Annual Meeting of the American Association for Cancer
Research today, Quintessence Biosciences presented the results
of the IND-enabling toxicology
studies for the Company’s lead cancer drug candidate, QBI-139. |
| |
5 February 2008 |
| Althea
Technologies Chosen by Quintessence Biosciences to Produce Lead
Protein Oncology Drug (PDF)
Althea Technologies, Inc., a leading provider of innovative technologies
and services for pharmaceutical development and manufacturing,
announced today that is has been awarded a contract from Quintessence
Biosciences under a manufacturing supply agreement to produce
the firm’s first drug candidate. |
| |
30 November 2007 |
| Quintessence
Biosciences, Inc. Announces Award of Two Federal Grants to Support
Development of EVade™ Ribonuclease Products
(PDF) The
National Cancer Institute awarded Quintessence Biosciences two
Phase 1 Small Business Innovation Research grants. |
| |
22 October 2007 |
| Quintessence
Biosciences, Inc. Presents Additional Data on Lead Candidate (PDF)
Quintessence Biosciences presented information about
the company’s lead candidate QBI-139 at the International
Conference on Molecular Targets and Cancer Therapeutics - the
premier international meeting featuring novel cancer therapeutics. |
| |
16
April 2007 |
| Quintessence
Biosciences, Inc. Presents Pre-clinical Toxicology Data at Cancer
Meeting (PDF)
At the Annual Meeting of the American Association for Cancer Research
today, Quintessence Biosciences presented pre-clinical toxicology
data on the performance of the Company’s lead cancer drug
candidate, QBI-139 for treatment of patients with solid tumors. |
| |
8
February 2007 |
| Quintessence
Biosciences, Inc. Names Laura Strong, Ph.D. as President
(PDF)
Quintessence Biosciences today announced the appointment of Laura
Strong, Ph.D. to the position of the Company’s President
and Chief Operating Officer. |
| |
9
November 2006 |
| Quintessence
Biosciences Confirms Selection of EVade™ Ribonuclease Cancer
Treatment for Late Stage Pre-Clinical Studies (PDF)
Quintessence Biosciences, Inc. today confirmed the selection of
a compound from its proprietary EVade™ Ribonuclease program
for advancement to pre-clinical testing and human clinical trials. |
| |
19
April 2005 |
| Quintessence
Biosciences Announces Start of Non-Clinical Studies on Lead Candidate
QBI-139 at the 2005 Annual Meeting of the American Association
of Cancer Research (PDF) |
| |
